维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

9篇 您的检索式：作者名="Ben RA"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Evaluation of the Sysmex UF-100 automated urinalysis analyzer 显示文摘	Ben Ezra J Bork L McPherson RA	1998	Clin Chem1998，44，1：	1
	2	Volatile fatty acids,lactic acid,and ph in the stools of breast-fed and bottle-fed infants显示文摘	Ogawa K Ben RA Pons S	1992	J Pediatr Gastroenterol Nutr1992，15，：	1
	3	Transmission analysis of OFDM - Based wireless services over turbulent Radio - on - FSO links modeled by Gamma-Gamma distribution显示文摘	Abdelmoula Bekkali Chedlia Ben Naila Kamugisha Kazau- ra	2010	IEEE Photonics Journal2010，2，3：	1
	4	Sleep and psychiatric disorder显示文摘	Ben RM Obermeyer WH Thiated RA	1992	Arc Gen Psychiatry1992，49，：	1
	5	The signals and pathways activating cellular senescence 显示文摘	Ben - Porath I Weinberg RA	2005	International Journal of Biochemistry and Cell Biology2005，37，5：	1
	6	A case of pleuropericarditis preceding acute lymphoblastic leukemia显示文摘	Zitouna M Kaabar A Ben RA	1984	Tunis Med1984，62，2：	1
	7	Evaluation of the Sysmex UF- IO0 automated urinalysis analyzer 显示文摘	Ben - Ezra J Bork L McPherson RA	1998	ClinChem1998，44，1：	1
	8	The signals and pathways activating cellular senescence 显示文摘	Ben - Porath I Weinberg RA	2005	Int J Biochem Cell Biol2005，37，5：	1
	9	Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar(CT-P13)in patients with inflammatory bowel disease显示文摘BACKGROUND Infliximab original has changed the natural history of inflammatory bowel diseases(IBD) over the past two decades. However, the recent expiration of its patent has allowed the entry of the first Infliximab biosimilar into the European and Spanish markets. Currently switching drugs data in IBD are limited. AIM To compare the efficacy of infliximab biosimilar, CT-P13, against infliximab original, analyzing the loss of response of both at the 12 mo follow-up in patients with IBD.METHODS An observational study of two cohorts has been conducted. One retrospective cohort that included patients with IBD treated with Infliximab original, and a prospective cohort of patients who were switching from infliximab original to infliximab biosimilar(CT-P13). We had analyzed the overall efficacy and loss of efficacy in patients in remission at the end of one year after treatment with the original drug compared to the results of the year of treatment with the biosimilar.RESULTS98 patients(CD 67, CU 31) were included in both cohorts. The overall efficacy for infliximab original per year of treatment was 71% vs 68.2% for infliximab biosimilar(P = 0.80). The loss of overall efficacy at 12 mo for infliximab original was 6.6% vs 14.5% for infliximab biosimilar(P = 0.806). The loss of efficacy in patients who were in basal remission was 16.3% for infliximab original vs 27.1% for infliximab biosimilar. Adverse events were 9.2% for infliximab original vs 11.2% for infliximab biosimilar. CONCLUSION The overall efficacy and loss of treatment response with infliximab biosimilar(CT-P13) is similar to that observed with infliximab original in patients who were switching at the 12 mo follow-up. There is no difference in the rate of adverse events.	María Fernanda Guerra Veloz Federico Argüelles-Arias Luisa Castro Laria Belén Maldonado Pérez Antonio Benítez Roldan Raúl Perea Amarillo Vicente Merino Bohórquez Miguel Angel Calleja Angel Caunedo Alvarez Angel Vilches Arenas	2018	World Journal of Gastroenterology2018，24，46：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费